In conclusion we show that antibody responses following Covid-19 vaccination are reduced in patients with CLL, with patients who are IgA-deficient or on BTKi therapy at particular risk for failure to develop a response. The gene discussed is CD79A; the disease is B-cell chronic lymphocytic leukemia.